Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma

Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma

For patients with newly diagnosed metastatic melanoma, rapid BRAF mutation (mBRAF) assessment is vital to promptly initiate systemic therapy. Additionally, blood-based biomarkers are desired to monitor and predict treatment response. Circulating tumor DNA (ctDNA) has shown great promise for minimall...

Full description

Bibliographic Details
Main Authors: Sofie H. Tolmeijer, Rutger H. T. Koornstra, Jan Willem B. de Groot, Maartje J. Geerlings, Dirk H. van Rens, Marye J. Boers-Sonderen, Jack A. Schalken, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
circulating tumor DNA (ctDNA), BRAF
biomarker
lactate dehydrogenase (LDH), S100
melanoma
Online Access:https://www.mdpi.com/2072-6694/13/15/3913

Internet

https://www.mdpi.com/2072-6694/13/15/3913

Similar Items